BB Biotech Spots Potential In Esperion Therapeutics (ESPR); Tempur Sealy Intl (TPX) Tumbles on Bearish Outlook


Esperion Therapeutics, Inc. (Nasdaq:ESPR) stock surged 1.40% (or +$0.19) to $13.74 with a total volume of 452,281 shares traded on Tuesday

After the closing bell, BB Biotech AG disclosed in a regulatory filing ( SC 13G ) with the U.S. Securities and Exchange Commission (SEC) a 5.1% passive stake (1,158,542 shares) in the biopharmaceutical company

Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), has 22.55M Shares Outstanding, Market Capitalization (intraday) of $309.84M and ESPR stock 52-week range is from $9.58 to $39.23 per share



Shares of Tempur Sealy International, Inc. (NYSE:TPX) plunge by more than 20% in the extended session Tuesday after the company said that net sales for the current quarter would be below its prior forecast, also expecting a decline year-over-year of 1% to 3% in net sales for the full year 2016 and representing numbers below Wall Street analysts’ estimates for the period

Tempur Sealy expects to release its third quarter 2016 earnings report on Thursday, October 27, 2016

TPX stock closed at $74.45, down $0.05 (or -0.07%) and 1.84M of its shares changed hands during the day

Tempur Sealy International, which develops, manufactures, markets, and distributes bedding products worldwide, has 58.41M Shares Outstanding and TPX stock one-year range is between $50.80 and $82.61 per share. At close on Tuesday, the company had a Market Capitalization of $4.35B


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at